Nielsen enters agreement with Vial for assistance in phase 3 Candin trial
Click Here to Manage Email Alerts
Key takeaways:
- Vial is a contract research organization that offers a technology platform for the organization of clinical trials.
- Nielsen has partnered with Vial for its phase 3 study of Candin.
Vial has entered a partnership with Nielsen BioSciences Inc. to support Nielsen’s phase 3 trial of Candin for the treatment of verruca vulgaris, according to a company press release.
This partnership is the second for Nielsen BioSciences recently. The company entered an agreement with Maruho Co. Ltd. just last month to grant Maruho the exclusive license to market Candin in Japan.
“Collaborating with the Vial team on our phase 3 trial, along with partnering with Maruho to enter the Japanese market, puts Nielsen BioSciences in an excellent position to bring this potentially groundbreaking treatment for common warts across the finish line," David P. Burney, PhD, MBA, president and COO of Nielsen BioSciences, told Healio.
Vial is a contract research organization that offers a technology platform to make trials more efficient from start to finish. The partnership will help facilitate Nielsen’s phase 3, randomized, double-blind, placebo-controlled clinical trial of Candin, a diagnostic skin test for the treatment of verruca vulgaris, or common warts.
As Candin is currently not approved by the FDA, enrollment for this trial is expected to begin in the second half of 2023 with a study conclusion anticipated in mid-2025, according to Burney.
Read more about
Click Here to Manage Email Alerts